Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

Published
10 March 2014
From
HIV i-Base
Higher pill burden is associated with poorer adherence to HIV therapy and reduced chances of achieving an undetectable viral load

Lower pill burden is associated with higher rates of adherence to HIV treatment and better virological outcomes, according to the results of a meta-analysis published in the online

Published
31 January 2014
By
Michael Carter
Successful HIV drug resistance testing is possible when viral load is low

HIV drug resistance testing can perform well, even when viral load is as low as 250 copies/ml, results of two studies published in the online edition of

Published
27 January 2014
By
Michael Carter
U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.

Published
16 December 2013
From
Gilead press release
Once-daily raltegravir effective as maintenance therapy

Almost all HIV-positive people with undetectable viral load who switched to once-daily raltegravir (Isentress) maintained viral suppression, French researchers reported at the 14th European AIDS Conference this

Published
31 October 2013
By
Liz Highleyman
Once-daily raltegravir for 48 weeks as maintenance therapy in Paris

Sixty-eight of 71 people who switched to once-daily raltegravir with a viral load below 50 copies maintained virologic suppression for 48 weeks in an observational study at a Paris hospital. Virologic failure occurred in 3 people taking nucleos(t)ides with raltegravir who had a previous nucleos(t)ide failure.

Published
22 October 2013
From
NATAP
TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

Published
19 September 2013
From
NATAP
Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

Published
13 September 2013
From
NATAP
Lessons Learned When the Labs Go Awry

David Fawcett describes the feelings - and the lessons - when a rebound in viral load resulted in a change of his HIV medication.

Published
10 September 2013
From
TheBody.com
Persisently detectable viral load at any level increases risk of HIV treatment failure

For people taking HIV therapy, a persistent detectable viral load at any level is associated with an increased risk of virologic failure, Canadian research published in the online

Published
29 August 2013
By
Michael Carter
← First12345...23Next →

Filter by country